The cardiovascular system medicine sales in Japan are forecasted to see a modest increase over the coming years, with the value expected to move from 66.2 USD per capita in 2024 to 67.3 USD per capita by 2028. Year-on-year increments are consistently small, indicating a stable yet slow growth. Looking back, by 2023, the values were relatively similar to the 2024 forecast, underscoring a steady path for the market without significant deviations. The compound annual growth rate (CAGR) over the five-year period ending in 2028 will likely showcase a minor average annual increase.

Future trends to watch for include:

Demographic shifts such as an aging population potentially boosting demand for cardiovascular medicines.
Advancements in medical technology that may influence cardiovascular treatment preferences and sales.
Economic factors affecting healthcare spending and per capita purchasing power.